Anaplastic thyroid carcinoma (ATC) is the most aggressive form of thyroid cancer. It shows a
wide spectrum of morphological presentations and the diagnosis could be challenging due …

Abstract The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and
dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas …

The transdifferentiation of epithelial cells toward a mesenchymal condition (EMT) is a
complex process that allows tumor cells to migrate to ectopic sites. Cadherins are not just …

Objective To investigate the mutant status of BRAF gene and analyze its relationship to
epidemiological risk factors and clinical outcomes among patients with papillary thyroid …

Simple Summary Histopathological diagnosis is prone to significant observer variation in the
diagnosis of papillary thyroid carcinomas (PTCs) due to different thresholds of malignancy …

The use of the BRAF inhibitor vemurafenib exhibits drug resistance in the treatment of
thyroid cancer (TC), and finding more effective multitarget combination therapies may be an …

Simple Summary This study aimed to investigate the relationship between the allele
frequency (AF) of the BRAF V600E mutation and the histopathological features of papillary …

Background: The incidence of papillary thyroid cancer is increasing worldwide due to more
frequent pathological detection of papillary thyroid microcarcinomas (PTMC), which are …

Background: Thyroid cancer (TC) has one of the fastest increasing incidences worldwide
and primarily involves papillary thyroid cancer (PTC). The BRAFV600E mutation is the most …

Aberrant re-activation of transcription factors occurs frequently in cancer. Recently, we found
the basic helix-loop-helix transcription factors DEC1 and DEC2 significantly up-regulated in …